Correction: The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer

被引：0
|
作者：
C. Hage
V. Rausch
N. Giese
T. Giese
F. Schönsiegel
S. Labsch
C. Nwaeburu
J. Mattern
J. Gladkich
I. Herr
机构：
[1] University Clinic of Heidelberg,Section Surgical Research, Molecular OncoSurgery
[2] University of Heidelberg,Department of General Surgery, Institute for Immunology
[3] University of Heidelberg,Department of Molecular Immunodiagnostics, Institute for Immunology
来源：
Cell Death & Disease | / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer
    Delitto, Daniel
    Vertes-George, Eva
    Hughes, Steven J.
    Behrns, Kevin E.
    Trevino, Jose G.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (26) : 8458 - 8470
  • [22] c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer
    Daniel Delitto
    Eva Vertes-George
    Steven J Hughes
    Kevin E Behrns
    Jose G Trevino
    World Journal of Gastroenterology, 2014, (26) : 8458 - 8470
  • [23] A new preclinical GSK3β inhibitor overcomes acquired resistance to gemcitabine in pancreatic cancer
    Domoto, Takahiro
    Uehara, Masahiro
    Takenaka, Satoshi
    Miyashita, Tomoharu
    Minamoto, Toshinari
    CANCER SCIENCE, 2024, 115 : 286 - 286
  • [24] Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
    Park, Chi Hoon
    Cho, Sung Yun
    Ha, Jae Du
    Jung, Heejung
    Kim, Hyung Rae
    Lee, Chong Ock
    Jang, In-Young
    Chae, Chong Hak
    Lee, Heung Kyoung
    Choi, Sang Un
    BMC CANCER, 2016, 16
  • [25] Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
    Chi Hoon Park
    Sung Yun Cho
    Jae Du Ha
    Heejung Jung
    Hyung Rae Kim
    Chong Ock Lee
    In-Young Jang
    Chong Hak Chae
    Heung Kyoung Lee
    Sang Un Choi
    BMC Cancer, 16
  • [26] The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer
    Ting He
    Yinglei Gao
    Yanfen Fang
    Yangming Zhang
    Shuwei Zhang
    Fajun Nan
    Jian Ding
    Yi Chen
    Cancer Biology & Medicine, 2022, 19 (08) : 1172 - 1192
  • [27] The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKK? and overcomes gefitinib resistance in non-small cell lung cancer
    He, Ting
    Gao, Yinglei
    Fang, Yanfen
    Zhang, Yangming
    Zhang, Shuwei
    Nan, Fajun
    Ding, Jian
    Chen, Yi
    CANCER BIOLOGY & MEDICINE, 2022, 19 (08) : 1172 - 1192
  • [28] C-MET: A POTENTIAL CANDIDATE OF GLIOBLASTOMA CANCER STEM CELL MARKER
    Nam, Do-Hyun
    Joo, Kyeung Min
    Jin, Juyoun
    Kim, Mi Hyun
    Kong, Doo-Sik
    Lee, Jung-Il
    Park, Kwan
    Kim, Jong Hyun
    NEURO-ONCOLOGY, 2008, 10 (05) : 903 - 903
  • [29] Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib
    Kim, Junyeol
    Lee, Tae Seung
    Lee, Myeong Hwan
    Cho, In Rae
    Ryu, Ji Kon
    Kim, Yong-Tae
    Lee, Sang Hyub
    Paik, Woo Hyun
    CANCERS, 2024, 16 (05)
  • [30] HGF/c-met mRNA expressions in pancreatic cancer cell and cancer stromal cell compartments
    Nakahashi, C
    Oda, T
    Aoyagi, Y
    Kinoshita, T
    Fukao, K
    Ochiai, A
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 243 - 244
12345